Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
30
AMRN Quote, Financials, Valuation and Earnings
Last price:
$13.75
Seasonality move
:
18.48%
Day range:
$13.51 - $13.91
52-week range:
$7.08 - $20.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.17x
P/B ratio:
0.62x
Volume:
85.2K
Avg. volume:
85K
1-year change:
49.99%
Market cap:
$285.9M
Revenue:
$228.7M
EPS (TTM):
-$4.17
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
$43.1M | -- | -18% | -100% | $12.00 |
|
AKTX
Akari Therapeutics Plc
|
-- | -$0.11 | -- | -53.67% | $3.53 |
|
CLLS
Cellectis SA
|
$9.6M | -$0.10 | -5.7% | -56.58% | $7.20 |
|
DBVT
DBV Technologies SA
|
$889.9K | -$0.34 | -- | -80.11% | $40.03 |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.1B | $5.85 | 6.17% | 106.38% | $213.00 |
|
TRIB
Trinity Biotech Plc
|
$7.5M | -$0.57 | -33.73% | -28.57% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
$13.75 | $12.00 | $285.9M | -- | $0.00 | 0% | 7.17x |
|
AKTX
Akari Therapeutics Plc
|
$0.27 | $3.53 | $9.6M | -- | $0.00 | 0% | -- |
|
CLLS
Cellectis SA
|
$4.84 | $7.20 | $485.6M | -- | $0.00 | 0% | 6.02x |
|
DBVT
DBV Technologies SA
|
$19.03 | $40.03 | $520.7M | -- | $0.00 | 0% | -- |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$170.80 | $213.00 | $10.4B | 15.09x | $0.00 | 0% | 2.51x |
|
TRIB
Trinity Biotech Plc
|
$1.02 | -- | $19M | -- | $0.00 | 0% | 0.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
1.45% | 2.841 | 1.98% | 2.35x |
|
AKTX
Akari Therapeutics Plc
|
8.54% | -2.620 | 6.43% | 0.16x |
|
CLLS
Cellectis SA
|
54.27% | 0.665 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -1.892 | 5.85% | 1.41x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.150 | 67.81% | 1.24x |
|
TRIB
Trinity Biotech Plc
|
147.47% | 1.094 | 785.94% | 0.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMRN
Amarin Corp. Plc
|
$21.2M | -$1.7M | -17.51% | -17.79% | -3.42% | -$12.8M |
|
AKTX
Akari Therapeutics Plc
|
-- | -$2.2M | -82.27% | -91.86% | -- | -$2.1M |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
|
TRIB
Trinity Biotech Plc
|
$5.3M | -$2.2M | -45.03% | -- | -11.29% | -$6.3M |
Amarin Corp. Plc vs. Competitors
-
Which has Higher Returns AMRN or AKTX?
Akari Therapeutics Plc has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of --. Amarin Corp. Plc's return on equity of -17.79% beat Akari Therapeutics Plc's return on equity of -91.86%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M AKTXAkari Therapeutics Plc-- -$0.19 $24.8M -
What do Analysts Say About AMRN or AKTX?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -12.15%. On the other hand Akari Therapeutics Plc has an analysts' consensus of $3.53 which suggests that it could grow by 1340.41%. Given that Akari Therapeutics Plc has higher upside potential than Amarin Corp. Plc, analysts believe Akari Therapeutics Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 AKTXAkari Therapeutics Plc2 0 0 -
Is AMRN or AKTX More Risky?
Amarin Corp. Plc has a beta of 0.708, which suggesting that the stock is 29.246% less volatile than S&P 500. In comparison Akari Therapeutics Plc has a beta of 0.279, suggesting its less volatile than the S&P 500 by 72.076%.
-
Which is a Better Dividend Stock AMRN or AKTX?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Akari Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or AKTX?
Amarin Corp. Plc quarterly revenues are $49.4M, which are larger than Akari Therapeutics Plc quarterly revenues of --. Amarin Corp. Plc's net income of -$7.7M is lower than Akari Therapeutics Plc's net income of -$6.4M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Akari Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 7.17x versus -- for Akari Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc7.17x -- $49.4M -$7.7M AKTXAkari Therapeutics Plc-- -- -- -$6.4M
-
Which has Higher Returns AMRN or CLLS?
Cellectis SA has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of 1.68%. Amarin Corp. Plc's return on equity of -17.79% beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About AMRN or CLLS?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -12.15%. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 48.76%. Given that Cellectis SA has higher upside potential than Amarin Corp. Plc, analysts believe Cellectis SA is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 CLLSCellectis SA2 2 0 -
Is AMRN or CLLS More Risky?
Amarin Corp. Plc has a beta of 0.708, which suggesting that the stock is 29.246% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.784%.
-
Which is a Better Dividend Stock AMRN or CLLS?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or CLLS?
Amarin Corp. Plc quarterly revenues are $49.4M, which are larger than Cellectis SA quarterly revenues of $35M. Amarin Corp. Plc's net income of -$7.7M is lower than Cellectis SA's net income of $586.4K. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 7.17x versus 6.02x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc7.17x -- $49.4M -$7.7M CLLSCellectis SA6.02x -- $35M $586.4K
-
Which has Higher Returns AMRN or DBVT?
DBV Technologies SA has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of --. Amarin Corp. Plc's return on equity of -17.79% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About AMRN or DBVT?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -12.15%. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 109.38%. Given that DBV Technologies SA has higher upside potential than Amarin Corp. Plc, analysts believe DBV Technologies SA is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 DBVTDBV Technologies SA4 0 1 -
Is AMRN or DBVT More Risky?
Amarin Corp. Plc has a beta of 0.708, which suggesting that the stock is 29.246% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.
-
Which is a Better Dividend Stock AMRN or DBVT?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or DBVT?
Amarin Corp. Plc quarterly revenues are $49.4M, which are larger than DBV Technologies SA quarterly revenues of --. Amarin Corp. Plc's net income of -$7.7M is higher than DBV Technologies SA's net income of -$33M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 7.17x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc7.17x -- $49.4M -$7.7M DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns AMRN or JAZZ?
Jazz Pharmaceuticals Plc has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of 22.33%. Amarin Corp. Plc's return on equity of -17.79% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B -
What do Analysts Say About AMRN or JAZZ?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -12.15%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $213.00 which suggests that it could grow by 24.71%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Amarin Corp. Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 JAZZJazz Pharmaceuticals Plc10 2 0 -
Is AMRN or JAZZ More Risky?
Amarin Corp. Plc has a beta of 0.708, which suggesting that the stock is 29.246% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.305, suggesting its less volatile than the S&P 500 by 69.522%.
-
Which is a Better Dividend Stock AMRN or JAZZ?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or JAZZ?
Amarin Corp. Plc quarterly revenues are $49.4M, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Amarin Corp. Plc's net income of -$7.7M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 7.17x versus 2.51x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc7.17x -- $49.4M -$7.7M JAZZJazz Pharmaceuticals Plc2.51x 15.09x $1.1B $251.4M
-
Which has Higher Returns AMRN or TRIB?
Trinity Biotech Plc has a net margin of -15.58% compared to Amarin Corp. Plc's net margin of -31.41%. Amarin Corp. Plc's return on equity of -17.79% beat Trinity Biotech Plc's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M TRIBTrinity Biotech Plc35.03% -$0.46 $55.5M -
What do Analysts Say About AMRN or TRIB?
Amarin Corp. Plc has a consensus price target of $12.00, signalling downside risk potential of -12.15%. On the other hand Trinity Biotech Plc has an analysts' consensus of -- which suggests that it could grow by 1370.59%. Given that Trinity Biotech Plc has higher upside potential than Amarin Corp. Plc, analysts believe Trinity Biotech Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp. Plc0 1 1 TRIBTrinity Biotech Plc0 0 0 -
Is AMRN or TRIB More Risky?
Amarin Corp. Plc has a beta of 0.708, which suggesting that the stock is 29.246% less volatile than S&P 500. In comparison Trinity Biotech Plc has a beta of 0.489, suggesting its less volatile than the S&P 500 by 51.129%.
-
Which is a Better Dividend Stock AMRN or TRIB?
Amarin Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp. Plc pays -- of its earnings as a dividend. Trinity Biotech Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or TRIB?
Amarin Corp. Plc quarterly revenues are $49.4M, which are larger than Trinity Biotech Plc quarterly revenues of $15.2M. Amarin Corp. Plc's net income of -$7.7M is lower than Trinity Biotech Plc's net income of -$4.8M. Notably, Amarin Corp. Plc's price-to-earnings ratio is -- while Trinity Biotech Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp. Plc is 7.17x versus 0.31x for Trinity Biotech Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp. Plc7.17x -- $49.4M -$7.7M TRIBTrinity Biotech Plc0.31x -- $15.2M -$4.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
